Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751450 | 0.91 | CYP11B2 (0.43) | CYP11B2CYP11B1CASP1SLC22A12 | |
| SCHEMBL751927 | 0.82 | CYP11B2 (0.43) | CYP11B2CYP11B1CASP1 | |
| SCHEMBL3750952 | 0.82 | CYP11B2 (0.45) | CYP11B2CYP11B1CASP1CTSCSLC22A12 | |
| SCHEMBL3748498 | 0.80 | CYP11B2 (0.51) | CYP11B2CYP11B1 | |
| SCHEMBL3750947 | 0.78 | CYP11B2 (0.46) | CYP11B2CYP11B1CTSCSLC22A12 | |
| SCHEMBL3751446 | 0.78 | CYP11B1 (0.43) | CYP11B2CYP11B1CTSCSLC22A12 | |
| SCHEMBL3755079 | 0.76 | CYP11B2 (0.44) | CYP11B2CYP11B1CTSCSLC22A12 | |
| SCHEMBL15435101 | 0.76 | CYP11B2 (0.46) | CYP11B2CYP11B1CTSCSLC22A12 | |
| SCHEMBL746432 | 0.76 | CYP11B2 (0.40) | CYP11B2CYP11B1CASP1SLC22A12 | |
| SCHEMBL3750955 | 0.76 | CYP11B2 (0.47) | CYP11B2CYP11B1CTSCSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| WO-2013008164-A2 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2012065956-A1 | SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | CYP11B2 335/4885CYP11B1 78/4885CASP1 141/4885 |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885CASP1 2598/4885 |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | CYP11B2 335/4885CYP11B1 78/4885CASP1 141/4885 |
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | REN, MME, AGTR1 | CYP11B2 1302/4885CYP11B1 640/4885CASP1 2921/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | CYP11B2 335/4885CYP11B1 78/4885CASP1 141/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | CYP11B2 817/4885CYP11B1 411/4885CASP1 319/4885 |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CYP11B2 995/4885CYP11B1 696/4885CASP1 4148/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | CYP11B2 403/4885CYP11B1 157/4885CASP1 295/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885CASP1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.